{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029822","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.950938+00:00","generated_at":"2026-06-11T05:47:13.960847+00:00","sec_items":["1.01","3.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immix Biopharma raises $10M via private placement; appoints new director","bullets":["Gross proceeds of ~$10M from sale of 3.24M shares at $1.94/share and 1.91M pre-funded warrants at $1.9399.","Net proceeds of ~$9.55M; funds to be used for working capital and general corporate purposes.","Pre-funded warrants exercisable at $0.0001/share, no expiration, with 19.99% blocker provision.","Company to file resale registration statement within 30 days, seek effectiveness within 45 days.","Yekaterina Chudnovsky appointed to board as independent director effective August 22, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029822","json":"https://secwatch.observer/filing/0001493152-23-029822.json","markdown":"https://secwatch.observer/filing/0001493152-23-029822.md","text":"https://secwatch.observer/filing/0001493152-23-029822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223029822/0001493152-23-029822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223029822/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:47:13.960847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d97e41f598","claim":"Yekaterina Chudnovsky was appointed as Director at Immix Biopharma, Inc..","evidence_excerpt":"Effective August 22, 2023 and in connection with the closing of the Private Placement, the Board of Directors (the “Board”) of the Company appointed Yekaterina Chudnovsky as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223029822/0001493152-23-029822-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7ce95fb117981d9603b84da2893c20f652cc8a45","claim":"Immix Biopharma, Inc. entered into Securities Purchase Agreement with a certain accredited investor valued at approximately $10 million (effective 2023-08-21).","evidence_excerpt":"On August 21, 2023, Immix Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with a certain accredited investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue to the Purchaser in a private placement transaction (the “Private Placement”) (i) 3,241,076 shares (the “Shares”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and (ii) pre-funded warrants to purchase 1,913,661 shares of Common Stock (the “Pre-Funded Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223029822/0001493152-23-029822-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a certain accredited investor"},{"label":"Value","value":"approximately $10 million"},{"label":"Effective","value":"2023-08-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}